Common Contracts
2 similar Clinical Trial Collaboration Agreement contracts by BioXcel Therapeutics, Inc.
EX-10.1 2 btai-20180930ex10136c792.htm EX-10.1 EXECUTION VERSION CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WHERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE...Clinical Trial Collaboration Agreement • May 5th, 2020 • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of September 21, 2018 (the “Effective Date”) by and between BioXcel Therapeutics, a Delaware corporation, headquartered at 780 East Main Street, Branford, CT 06405 (“BioXcel”), and Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”). BioXcel and Nektar may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • November 9th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of September 21, 2018 (the “Effective Date”) by and between BioXcel Therapeutics, a Delaware corporation, headquartered at 780 East Main Street, Branford, CT 06405 (“BioXcel”), and Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”). BioXcel and Nektar may be referred to herein individually as a “Party,” or collectively as the “Parties.”
